CHRS250516C3000
- 0.05
- 0.000.00%
Coherus BioSciences Newsroom
Coherus to Participate in Upcoming Investor Conferences
H.C. Wainwright Maintains Coherus BioSciences(CHRS.US) With Buy Rating, Maintains Target Price $7
Express News | HC Wainwright & Co. Reiterates Buy on Coherus BioSciences, Maintains $7 Price Target
Promising Clinical Data and Strategic Expansion Justify Buy Rating for Coherus Biosciences
Coherus BioSciences Reports Promising Clinical Data for CHS-114 Combined With Toripalimab in HNSCC and Gastric Cancer
Coherus Biosciences: Data From Ongoing Phase 1 Clinical Trial Evaluating CHS-114 Shows Clinical Efficacy And Proof Of Mechanism In HNSCC In Combination With Toripalimab
Coherus Presents Promising Early Clinical Data From Phase 1 Dose Expansion Study of CHS-114 in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025
Coherus BioSciences Price Target Cut to $1.05/Share From $1.50 by UBS
Coherus BioSciences Is Maintained at Neutral by UBS
Coherus BioSciences Analyst Ratings
New Analyst Forecast: $CHRS Given $1.05 Price Target
Coherus Biosciences CCO Resigns After UDENYCA Divestiture
Sector Update: Health Care
Coherus BioSciences Completes Sale of Udenyca Franchise to Intas Pharmaceuticals for Up to $558.4 Million
Express News | Accord Biopharma, Inc. Announces Completion of Udenyca® (Pegfilgrastim-Cbqv) Franchise Acquisition From Coherus BioSciences, Inc., Expanding U.S. Biosimilar Portfolio
Express News | Coherus Completes Strategic Transformation With Successful Divestiture of Udenyca® Franchise
Coherus Completes Strategic Transformation With Successful Divestiture of UDENYCA Franchise
Coherus Announces Repurchase of Approximately $170 Million of Convertible Notes
Investors Don't See Light At End Of Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Tunnel And Push Stock Down 27%
Express News | Coherus To Present Data From Phase 1 Dose Expansion Study Of CHS-114 At 2025 American Association For Cancer Research Annual Meeting